Paradoxically, Abdel-Wahab and colleagues found that TET2 mutations were linked to worse OS in 93 patients with de novo AML, and a recent whole-exome sequencing study reported worse EFS in AML patients with TET2 mutation (Abdel-Wahab et al., 2009; Weissmann et al., 2012). This evidence concerns the gene TET2 and acute myeloid leukemia.